Yabao Pharmaceutical Group Co., Ltd

600351

CNE000001CM5

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
6.56 ^CNY	+1.23%		+6.67%	-4.93%

Apr. 25	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback.

February 04, 2024

On February 5, 2024, the company announced an increase in its equity buyback plan. The company increased its authorization by an additional amount of CNY 300 million, thereby increasing the total plan term monetary value authorization to CNY 600 million.

Latest news about Yabao Pharmaceutical Group Co., Ltd

Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules	Apr. 16	MT
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	Apr. 01	CI
Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback.	Feb. 04	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	23-10-09	CI
Yabao Pharmaceutical Group Co., Ltd(XSSC:600351) added to S&P Global BMI Index	23-09-18	CI
Hunan Caprico Biotechnologies Co., Ltd. announced that it has received funding from Guangzhou Huangpu Biomedical Fund Management Co., Ltd., Yabao Pharmaceutical Group Co., Ltd	23-09-17	CI
Yabao Pharmaceutical Takes Over Rights of Traditional Chinese Medicine for 26 Million Yuan	23-08-08	MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	23-07-03	CI
Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.	23-05-08	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Yabao Pharmaceutical Unit Submits FDA Application for Osteoarthritis Drug	23-04-13	MT
Yabao Pharmaceutical Unit's Sorafenib Tablets Enters US Markets	22-11-16	MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor	22-08-02	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Indian Indices End Lower; Bajaj Finance Slides 7%	22-04-27	MT
Lupin to Market Pediatric Medicines in China Under New Deal with Yabao Pharmaceutical	22-04-27	MT
Lupin Limited and Yabao Pharmaceutical Co. Inc. Announce Strategic Partnership in China	22-04-27	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-22	CI

Chart Yabao Pharmaceutical Group Co., Ltd

Duration

Period

Chart Yabao Pharmaceutical Group Co., Ltd

More charts

Company Profile

YABAO PHARMACEUTICAL GROUP CO. LTD is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company mainly provides light pastes, tablets, injections, capsules, oral liquids, bulk drugs and other pharmaceutical products. The Company is also engaged in the wholesaling and trading of pharmaceuticals. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
YABAO PHARMACEUTICAL GROUP CO., LTD	-4.93%	640M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.52%	43.18B
OTSUKA HOLDINGS CO., LTD.	+20.67%	22.59B
SANDOZ GROUP AG	+15.34%	14.56B
ZYDUS LIFESCIENCES LIMITED	+43.20%	11.5B
ONO PHARMACEUTICAL CO., LTD.	-8.37%	6.93B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.36B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-2.27%	4.81B